P. Duffau, L. Wittkop, L. E. Le-marec, F. Cognet, C. Blanco et al., Association of immune-activation and senescence markers with non-AIDS-defining comorbidities in HIV-suppressed patients, AIDS, vol.29, issue.16, pp.2099-108, 2015.
URL : https://hal.archives-ouvertes.fr/hal-01288887

D. Group, N. Friis-moller, P. Reiss, C. A. Sabin, R. Weber et al., Class of antiretroviral drugs and the risk of myocardial infarction, N Engl J Med, vol.356, issue.17, pp.1723-1758, 2007.

A. R. Eckard, E. G. Meissner, I. Singh, and G. A. Mccomsey, Cardiovascular Disease, Statins, and HIV. The Journal of infectious diseases, vol.214, p.5021243, 2016.

F. Boccara, S. Lang, C. Meuleman, S. Ederhy, M. Mary-krause et al., HIV and coronary heart disease: time for a better understanding, J Am Coll Cardiol, vol.61, issue.5, pp.511-534, 2013.

S. Lang, M. Mary-krause, L. Cotte, J. Gilquin, M. Partisani et al., Impact of individual antiretroviral drugs on the risk of myocardial infarction in human immunodeficiency virus-infected patients: a casecontrol study nested within the French Hospital Database on HIV ANRS cohort CO4, Arch Intern Med, vol.170, issue.14, pp.1228-1266, 2010.

L. Ryom, J. D. Lundgren, W. El-sadr, P. Reiss, O. Kirk et al., Cardiovascular disease and use of contemporary protease inhibitors: the D:A:D international prospective multicohort study, Lancet HIV, 2018.

, Epub 2018/05/08, vol.5, pp.30043-30045

N. Gupta, T. Singh, R. Chaudhary, S. K. Garg, G. S. Sandhu et al., Bilirubin in coronary artery disease: Cytotoxic or protective?, World J Gastrointest Pharmacol Ther, vol.7, issue.4, p.5095566, 2016.

B. G. Brenner and J. G. Baril, Limiting cardiovascular events associated with HIV and antiretroviral therapy, AIDS, vol.31, issue.18, pp.2551-2554, 2017.

C. Katlama, L. Assoumou, M. A. Valantin, C. Soulie, E. Martinez et al., Dual therapy combining raltegravir with etravirine maintains a high level of viral suppression over 96 weeks in long-term experienced HIV-infected individuals over 45 years on a PI-based regimen: results from the Phase II ANRS 163 ETRAL study, The Journal of antimicrobial chemotherapy, vol.74, issue.9, pp.2742-51, 2019.

E. Martinez, L. Assoumou, G. Moyle, L. Waters, M. Johnson et al., 48-week changes in biomarkers in subjects with high cardiovascular risk boosted switching from ritonavir-protease inhibitors to dolutegravir: the NEAT022 study, Journal of the International AIDS Society, vol.21, issue.S8, p.25187, 2018.

J. M. Gatell, L. Assoumou, G. Moyle, L. Waters, M. Johnson et al., Immediate Versus Deferred Switching From a Boosted Protease Inhibitor-based Regimen to a Dolutegravir-based Regimen in Virologically Suppressed Patients With High Cardiovascular Risk or Age >/ = 50 Years: Final 96-Week Results of the NEAT022 Study, vol.68, pp.597-606, 2019.

A. M. Hill, N. Mitchell, S. Hughes, and A. L. Pozniak, Risks of cardiovascular or central nervous system adverse events and immune reconstitution inflammatory syndrome, for dolutegravir versus other antiretrovirals: meta-analysis of randomized trials, Curr Opin HIV AIDS, vol.13, issue.2, pp.102-113, 2018.

J. A. O'halloran, J. Sahrmann, A. M. Butler, M. A. Olsen, and W. G. Powderly, CARDIOVASCU-LAR DISEASE RISK ASSOCIATED WITH INTEGRASE INHIBITORS. CROI, 2019.

W. Venter, M. Moorhouse, S. Sokhela, L. Fairlie, N. Mashabane et al., Dolutegravir plus Two Different Prodrugs of Tenofovir to Treat HIV, N Engl J Med, vol.381, issue.9, pp.803-818, 2019.

A. Hill, L. Waters, and A. Pozniak, Are new antiretroviral treatments increasing the risks of clinical obesity?, J Virus Erad, vol.5, issue.1, pp.41-44, 2019.


. Seattle,


K. Bourgi, P. F. Rebeiro, M. Turner, J. L. Castilho, T. Hulgan et al., Clinical infectious diseases: an official publication of the Infectious Diseases Society of America, Epub 2019/05/18, 2019.

J. I. Bernardino, A. Mocroft, C. Wallet, S. De-wit, C. Katlama et al., Body composition and adipokines changes after initial treatment with darunavir-ritonavir plus either raltegravir or tenofovir disoproxil
URL : https://hal.archives-ouvertes.fr/hal-01999822

S. Dirajlal-fargo, C. Moser, T. T. Brown, T. Kelesidis, M. P. Dube et al., Changes in Insulin Resistance After Initiation of Raltegravir or Protease Inhibitors With Tenofovir-Emtricitabine: AIDS Clinical Trials Group A5260s, Open Forum Infect Dis, vol.3, issue.3, p.5047417, 2016.

J. Lo, J. Oyee, M. Crawford, R. Grove, R. Demasi et al., DOLUTEGRAVIR AND INSULIN RESISTANCE. CROI, 2019.

D. Francisci, M. Pirro, E. Schiaroli, M. R. Mannarino, S. Cipriani et al., Maraviroc Intensification Modulates Atherosclerotic Progression in HIV-Suppressed Patients at High Cardiovascular Risk. A Randomized, Crossover Pilot Study, Open Forum Infect Dis, vol.6, issue.4, p.6446135, 2019.

S. Piconi, D. Pocaterra, V. Rainone, M. Cossu, M. Masetti et al., Maraviroc Reduces Arterial Stiffness in PI-Treated HIV-infected Patients, Scientific reports, vol.6, p.4926207, 2016.

P. Afonso, M. Auclair, M. Caron-debarle, and J. Capeau, Impact of CCR5, integrase and protease inhibitors on human endothelial cell function, stress, inflammation and senescence, Antiviral therapy, vol.22, issue.8, pp.645-57, 2017.

O. Berger, X. Gan, C. Gujuluva, A. R. Burns, G. Sulur et al., CXC and CC chemokine receptors on coronary and brain endothelia, Mol Med, vol.5, issue.12, pp.795-805, 1999.

P. Central and P. , , p.2230493

J. J. Maguire, K. L. Jones, R. E. Kuc, M. C. Clarke, M. R. Bennett et al., The CCR5 chemokine receptor mediates vasoconstriction and stimulates intimal hyperplasia in human vessels in vitro, Cardiovascular research, vol.101, issue.3, p.3928001, 2014.

M. Auclair, P. Afonso, E. Capel, M. Caron-debarle, and J. Capeau, Impact of darunavir, atazanavir and lopinavir boosted with ritonavir on cultured human endothelial cells: beneficial effect of pravastatin, Antiviral therapy, vol.19, issue.8, pp.773-82, 2014.

L. B. Gano, A. J. Donato, H. M. Pasha, C. M. Hearon, A. L. Sindler et al., The SIRT1 activator SRT1720 reverses vascular endothelial dysfunction, excessive superoxide production, and inflammation with aging in mice, Am J Physiol Heart Circ Physiol, vol.307, issue.12, p.4269699, 2014.

R. L. Li, Z. Y. Lu, J. J. Huang, J. Qi, A. Hu et al., SRT1720, a SIRT1 specific activator, protected H2O2-induced senescent endothelium, Am J Transl Res, vol.8, issue.7, p.4969425, 2016.

E. X. Stavrou, C. Fang, A. Merkulova, O. Alhalabi, N. Grobe et al., Reduced thrombosis in Klkb1-/-mice is mediated by increased Mas receptor, prostacyclin, Sirt1, and KLF4 and decreased tissue factor, Blood, vol.125, issue.4, p.4304115, 2015.

F. C. Liu, Y. J. Day, J. T. Liou, H. P. Yu, and H. R. Liao, Splitomicin inhibits fMLP-induced superoxide anion production in human neutrophils by activate cAMP/PKA signaling inhibition of ERK pathway, Eur J Pharmacol, vol.688, issue.1-3, pp.68-75, 2012.

M. Mukohda, M. Stump, P. Ketsawatsomkron, C. Hu, F. W. Quelle et al., Endothelial PPARgamma provides vascular protection from IL-1beta-induced oxidative stress, Am J Physiol Heart Circ Physiol, vol.310, issue.1, p.4796462, 2016.

M. De-kerdanet, M. Caron-debarle, S. Nivot, T. Gaillot, O. Lascols et al., Ten-year improvement of insulin resistance and growth with recombinant human insulin-like growth factor 1 in a patient with insulin receptor mutations resulting in leprechaunism, Diabetes Metab, vol.41, issue.4, pp.331-338, 2015.

M. Auclair, C. Vigouroux, C. Desbois-mouthon, J. Deibener, P. Kaminski et al., Antiinsulin receptor autoantibodies induce insulin receptors to constitutively associate with insulin receptor substrate-1 and -2 and cause severe cell resistance to both insulin and insulin-like growth factor I. The Journal of clinical endocrinology and metabolism, vol.84, pp.3197-206, 1999.

S. An, L. P. Zhao, L. J. Shen, S. Wang, K. Zhang et al., USP18 protects against hepatic steatosis and insulin resistance through its deubiquitinating activity, Hepatology, vol.66, issue.6, pp.1866-84, 2017.

X. Liu, H. Li, B. Zhong, M. Blonska, S. Gorjestani et al., USP18 inhibits NF-kappaB and NFAT activation during Th17 differentiation by deubiquitinating the TAK1-TAB1 complex, J Exp Med, vol.210, issue.8, pp.1575-90, 2013.

P. Central and P. , , p.3727316

Z. Yang, H. Xian, J. Hu, S. Tian, Y. Qin et al., USP18 negatively regulates NF-kappaB signaling by targeting TAK1 and NEMO for deubiquitination through distinct mechanisms, Scientific reports, vol.5, 2015.

P. Central and P. ,

F. Artunc, E. Schleicher, C. Weigert, A. Fritsche, N. Stefan et al., The impact of insulin resistance on the kidney and vasculature, Nat Rev Nephrol, vol.12, issue.12, pp.721-758, 2016.

Y. Zhang, J. Wan, Z. Xu, T. Hua, and Q. Sun, Exercise ameliorates insulin resistance via regulating TGFbetaactivated kinase 1 (TAK1)-mediated insulin signaling in liver of high-fat diet-induced obese rats, J Cell Physiol, vol.234, issue.5, pp.7467-74, 2019.

E. Martinez, D. 'albuquerque, P. M. Llibre, J. M. Gutierrez, F. Podzamczer et al., Changes in cardiovascular biomarkers in HIV-infected patients switching from ritonavir-boosted protease inhibitors to raltegravir, AIDS, vol.26, issue.18, pp.2315-2341, 2012.

M. A. Noor, O. P. Flint, J. F. Maa, and R. A. Parker, Effects of atazanavir/ritonavir and lopinavir/ritonavir on glucose uptake and insulin sensitivity: demonstrable differences in vitro and clinically, AIDS, vol.20, issue.14, pp.1813-1834, 2006.

L. Waters, L. Assoumou, S. Rusconi, P. Domingo, M. Gompels et al., Switch to dolutegravir (DTG) from a boosted protease inhibitor (PI/r) associated with significant weight gain over 48 weeks in NEAT-022, a randomised 96-week trila, HIV Drug Therapy, 2018.

G. A. Mccomsey, C. Moser, J. Currier, H. J. Ribaudo, P. Paczuski et al., Body Composition Changes After Initiation of Raltegravir or Protease Inhibitors: ACTG A5260s. Clinical infectious diseases: an official publication of the Infectious Diseases Society of America, vol.62, p.4787610, 2016.

H. J. Stellbrink, J. R. Arribas, J. L. Stephens, H. Albrecht, P. E. Sax et al., Co-formulated bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir with emtricitabine and tenofovir alafenamide for initial treatment of HIV-1 infection: week 96 results from a randomised, double-blind, multicentre, phase 3, non-inferiority trial, Lancet HIV, vol.6, issue.6, pp.364-72, 2019.

J. E. Lake, The Fat of the Matter: Obesity and Visceral Adiposity in Treated HIV Infection, Current HIV/ AIDS reports, vol.14, issue.6, p.5694708, 2017.

O. Offor, N. Utay, D. Reynoso, A. Somasunderam, J. Currier et al., Adiponectin and the steatosis marker Chi3L1 decrease following switch to raltegravir compared to continued PI/NNRTI-based antiretroviral therapy, PloS one, vol.13, issue.5, p.5944924, 2018.

A. J. Donato, R. G. Morgan, A. E. Walker, and L. A. Lesniewski, Cellular and molecular biology of aging endothelial cells, J Mol Cell Cardiol, vol.89, p.4522407, 2015.

M. F. Oellerich and M. Potente, FOXOs and sirtuins in vascular growth, maintenance, and aging, Circ Res, vol.110, issue.9, pp.1238-51, 2012.

C. Cencioni, F. Spallotta, A. Mai, F. Martelli, A. Farsetti et al., Sirtuin function in aging heart and vessels, J Mol Cell Cardiol, vol.83, pp.55-61, 2015.

A. Basters, K. P. Knobeloch, and G. Fritz, USP18-a multifunctional component in the interferon response, Biosci Rep, vol.38, issue.6, 2018.

P. Central and P. , , p.6240716